Should enoxaparin be administered to a patient with severe multiple sclerosis who has active hematemesis?

No, enoxaparin should NOT be given to a patient with severe MS who has active hematemesis.

Active major bleeding is an absolute contraindication to enoxaparin administration. 1 The guideline explicitly states that low molecular weight heparin (LMWH), including enoxaparin, "should not be used in patients with active major bleeding at any site, tissue or organ." This is a clear, unequivocal contraindication that prioritizes patient safety and mortality risk.

Clinical Reasoning

Active hematemesis represents ongoing gastrointestinal hemorrhage—a life-threatening condition where anticoagulation would:

• Worsen existing bleeding by preventing hemostasis
• Increase mortality risk through exsanguination
• Cause potentially fatal hemorrhage as documented in adverse reactions 1

The multiple sclerosis diagnosis is irrelevant to this decision. The contraindication is based on the active bleeding, not the underlying neurological condition.

Management Algorithm

Immediate priorities:

1. Withhold all anticoagulation including enoxaparin
2. Resuscitate the patient (fluid resuscitation, blood products as needed)
3. Control the bleeding source (endoscopy, surgical consultation)
4. Monitor hemodynamics and hemoglobin closely

Once bleeding is controlled and hemostasis achieved:

• Consider mechanical thromboprophylaxis (graduated compression stockings, intermittent pneumatic compression) if VTE prophylaxis is needed 1
• Reassess bleeding risk before considering any pharmacologic anticoagulation
• If anticoagulation becomes necessary after stabilization, the bleeding risk must be weighed against thrombotic risk on an individual basis

Critical Pitfall

Do not rationalize starting enoxaparin "at a lower dose" or "with close monitoring" in the setting of active bleeding. The guideline states LMWH should be used with "extreme caution in patients with" conditions associated with bleeding risk 1, but active major bleeding is an absolute contraindication, not a precaution. The distinction is critical—precautions allow use with monitoring; contraindications prohibit use entirely.

The presence of active hematemesis makes enoxaparin administration potentially lethal and medically inappropriate.